Apotex Ruxolitinib Approval Date
Apotex's ruxolitinib cream 1.5% (generic for Incyte's Opzelura) gained FDA approval on October 20, 2024. This approval covers topical treatment for mild to moderate atopic dermatitis in non-immunocompromised patients aged 12 and older.[1]
What Conditions Does It Treat?
Like the reference product Opzelura, Apotex's version is approved for atopic dermatitis in patients 12+ and for nonsegmental vitiligo in patients 12+. It matches the branded cream's indications without additional trials required under FDA's 505(b)(2) pathway.[1][2]
How Does This Compare to Oral Ruxolitinib Generics?
Apotex also has an ANDA for oral ruxolitinib tablets (for myelofibrosis, polycythemia vera), but FDA has not yet approved it. Oral generics from other firms like Celgene (now Bristol Myers Squibb) face ongoing patent litigation, delaying entry until at least 2028. Topical approval came earlier due to shorter exclusivity for Opzelura.[3]
When Did Opzelura's Patent Protection End?
Incyte's Opzelura exclusivity expired September 21, 2024, allowing first generic approval shortly after. Core patents on ruxolitinib formulations extend to 2032-2036, but topical-specific ones lapsed sooner, enabling Apotex's entry. Check DrugPatentWatch.com for full patent details and challenges.[4]
Are Other Ruxolitinib Generics Approved?
Apotex is the first for the cream. Oral generics remain blocked; no FDA approvals yet despite multiple ANDA filings. Sandoz and Dr. Reddy's have tentative approvals for oral versions pending patent settlements.[3][4]
[1]: FDA Approval Letter for Apotex ruxolitinib cream, October 20, 2024 (fda.gov).
[2]: Opzelura Prescribing Information (incyte.com).
[3]: FDA Orange Book listings for ruxolitinib (fda.gov).
[4]: DrugPatentWatch.com/ruxolitinib (drugpatentwatch.com).